Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study-Reference-Cited by-同舟云学术

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study

Published:2021-04 Issue:4 Volume:3 Page:e253-e261
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Cavalli Giulio,Larcher Alessandro,Tomelleri Alessandro,Campochiaro Corrado,Della-Torre Emanuel,De Luca Giacomo,Farina Nicola,Boffini Nicola,Ruggeri Annalisa,Poli Andrea,Scarpellini Paolo,Rovere-Querini Patrizia,Tresoldi Moreno,Salonia Andrea,Montorsi Francesco,Landoni Giovanni,Castagna Antonella,Ciceri Fabio,Zangrillo Alberto,Dagna Lorenzo

Funder

Foundation for Research in Rheumatology

Ministero della Salute

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference33 articles.

1. COVID-19: consider cytokine storm syndromes and immunosuppression;Mehta;Lancet,2020

2. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China;Ruan;Intensive Care Med,2020

3. Tocilizumab in patients with severe COVID-19: a retrospective cohort study;Guaraldi;Lancet Rheumatol,2020